BioSpace News Archive

Amgen announced that the U.S. Food and Drug Administration has accepted a Biologics License Application and granted Priority Review for tezepelumab in the treatment of asthma.

Oncopeptides AB announces updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma who have received 2 – 4 prior lines of therapy.

Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve.

Sage Therapeutics, Inc. today announced that the Company will participate in a fireside chat at Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Summit on July 13 th at 2:25pm ET.

BioShin Limited announced the appointment of Dr. Zhihong Lu as Chief Medical Officer and Dr. Ma Li as Chief Commercial Officer.

Contrast medium or diagnostic imaging agent is a substance that enhances the contrast of structures and fluids present inside the body in medical imaging.

NMD Pharma A/S announces that it has initiated the ESTABLISH* study, an international observational study in collaboration with Aarhus University and The Ohio State University to assess neuromuscular function in patients with Charcot-Marie-Tooth disease, an inherited neuromuscular disorder of the peripheral nerves characterized by weakness and fatigue.

NovaBay® Pharmaceuticals, Inc., a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® for the beauty market, announces that management will participate at the upcoming investment conferences:

VBL Therapeutics announced the appointments of Alison Finger and Michael Rice to its Board of Directors, effective July 7, 2021.

Ikena Oncology, Inc. announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a panel discussing next-generation approaches to targeted oncology at the upcoming virtual William Blair Biotech Focus Conference.